Aktis Oncology, Inc. (AKTS)
Nasdaq · Pharmaceutical Preparations · Manufacturing · CIK 2035832 · fiscal year ends in Dec
Closing price $15.94 on 30 Oct 2026; 52-week range $15.06 to $32.23.
Key figures
The last twelve months reported, with the latest price and balance sheet.
- Market value
- $851.9M
- Cash
- $82.5M
- Debt
- $0
- Debt to equity
- 0.00
- Shares outstanding
- 53.4M
Financial statements
Revenue, profit and cash flow by fiscal year, each year linked to its annual report.
By quarter
| Quarter | Quarter end | Revenue | Net income | EPS |
|---|---|---|---|---|
| Q2 FY2026 | 30 Jun 2026 | $3.4M | -$24.1M | -$0.44 |
| Q1 FY2026 | 31 Mar 2026 | $3.2M | -$18.3M | -$0.38 |
| Q2 FY2025 | 30 Jun 2025 | $1.6M | -$18.1M | -$22.39 |
| Q1 FY2025 | 31 Mar 2025 | $1.4M | -$15.0M | -$18.60 |
Company events
The newest 8-K filings of 5 held.
| Filed | Form | Event | Items |
|---|---|---|---|
| 13 Aug 2026 | 8-K | Results | 2.02, 9.01 |
| 11 May 2026 | 8-K | Results | 2.02, 9.01 |
| 16 Apr 2026 | 8-K | Leadership change, Investor update | 5.02, 7.01, 9.01 |
| 30 Mar 2026 | 8-K | Results | 2.02, 9.01 |
| 12 Jan 2026 | 8-K | Bylaws or fiscal year change | 5.03, 9.01 |
Every filing
The newest filings with the SEC of 21 held.
| Filed | Form | Period |
|---|---|---|
| 13 Aug 2026 | 10-Q | 30 Jun 2026 |
| 13 Aug 2026 | 8-K | 13 Aug 2026 |
| 11 May 2026 | 10-Q | 31 Mar 2026 |
| 11 May 2026 | 8-K | 11 May 2026 |
| 16 Apr 2026 | 8-K | 15 Apr 2026 |
| 30 Mar 2026 | 8-K | 30 Mar 2026 |
| 30 Mar 2026 | 10-K | 31 Dec 2025 |
| 12 Jan 2026 | S-8 | – |
| 12 Jan 2026 | 8-K | 12 Jan 2026 |
| 8 Jan 2026 | EFFECT | – |
| 8 Jan 2026 | CERT | – |
| 7 Jan 2026 | 8-A12B | – |
Insider trades
Form 4 trades by officers, directors and 10% owners, last 12 months.
| Traded | Insider | Type | Shares | Price | Value | Held after | Form 4 |
|---|---|---|---|---|---|---|---|
| 23 Sep 2026 | Czibere Akos, Chief Medical Officer | Sale under a trading plan | 5,099 | $20.19 | $103.0K | 7,401 | 24 Sep 2026 |
| 23 Sep 2026 | Czibere Akos, Chief Medical Officer | Sale under a trading plan | 7,401 | $21.03 | $155.6K | 0 | 24 Sep 2026 |
| 20 Jul 2026 | Herrmann Ken, Director | Sale outside a trading plan | 3,506 | $24.56 | $86.1K | 1,350 | 21 Jul 2026 |
| 20 Jul 2026 | Herrmann Ken, Director | Sale outside a trading plan | 1,350 | $24.56 | $33.2K | 0 | 21 Jul 2026 |
| 17 Jul 2026 | Herrmann Ken, Director | Sale outside a trading plan | 3,065 | $25.21 | $77.3K | 0 | 20 Jul 2026 |
| 8 Jul 2026 | Ron-Bigger Shulamit, Chief Operating Officer | Sale outside a trading plan | 15,800 | $27.13 | $428.7K | 34,200 | 10 Jul 2026 |
| 8 Jul 2026 | Ron-Bigger Shulamit, Chief Operating Officer | Sale outside a trading plan | 30,000 | $27.94 | $838.1K | 4,200 | 10 Jul 2026 |
| 8 Jul 2026 | Ron-Bigger Shulamit, Chief Operating Officer | Sale outside a trading plan | 4,200 | $28.75 | $120.7K | 0 | 10 Jul 2026 |
| 8 Jul 2026 | Czibere Akos, Chief Medical Officer | Sale outside a trading plan | 14,800 | $27.13 | $401.5K | 35,200 | 10 Jul 2026 |
| 8 Jul 2026 | Czibere Akos, Chief Medical Officer | Sale outside a trading plan | 30,829 | $27.95 | $861.7K | 4,371 | 10 Jul 2026 |
| 8 Jul 2026 | Czibere Akos, Chief Medical Officer | Sale outside a trading plan | 4,371 | $28.71 | $125.5K | 0 | 10 Jul 2026 |
| 12 Jan 2026 | Foley Todd, Director | Purchase | 232,870 | $18.00 | $4.2M | 4,235,403 | 14 Jan 2026 |
Planned insider sales
Form 144 notices, filed when the sell order goes to the broker.
| Filed | Seller | Shares | Value | Planned sale |
|---|---|---|---|---|
| 23 Sep 2026 | Akos Czibere, Officer | 25,000 | $552.8K | 23 Sep 2026 |
| 20 Jul 2026 | KEN HERRMANN, Director | 4,856 | $119.3K | 20 Jul 2026 |
| 17 Jul 2026 | KEN HERRMANN, Director | 3,065 | $77.3K | 17 Jul 2026 |
| 8 Jul 2026 | SHULAMIT RON-BIGGER, Officer | 50,000 | $1.4M | 8 Jul 2026 |
| 8 Jul 2026 | AKOS CZIBERE, Officer | 50,000 | $1.4M | 8 Jul 2026 |
Large holders
Schedule 13D and 13G filings by holders of more than 5% of the voting shares.
| Filed | Holder | Schedule | Stake | Shares |
|---|---|---|---|---|
| 14 May 2026 | Blue Owl Capital Holdings LP | 13G | 5.92% | 3.2M |
| 20 Jan 2026 | MPM BIOVENTURES 2018, L.P. | 13D | 19.3% | 10.3M |
| 20 Jan 2026 | EcoR1 Capital, LLC | 13D | 9.1% | 4.9M |
| 15 Jan 2026 | Eli Lilly and Company | 13D | 11.9% | 6.3M |
| 14 Jan 2026 | Vida Ventures II, LLC | 13D | 10.9% | 5.8M |
Short interest
Shares sold short and not yet bought back, on each FINRA settlement date.
| Settlement | Shares short | Change | Days to cover |
|---|---|---|---|
| 15 Oct 2026 | 4.3M | -8.52% | 11.27 |
| 30 Sep 2026 | 4.7M | +44.98% | 7.3 |
| 15 Sep 2026 | 3.3M | +2.44% | 11.53 |
| 31 Aug 2026 | 3.2M | -7.89% | 10.36 |
| 14 Aug 2026 | 3.4M | -0.66% | 15.01 |
| 31 Jul 2026 | 3.5M | -7.24% | 12.84 |
| 15 Jul 2026 | 3.7M | +13.13% | 6.26 |
| 30 Jun 2026 | 3.3M | +13.49% | 4.99 |
Funds that hold it
From each fund's latest Form 13F.
119 funds held it at 30 Jun 2026: 77 added and 18 trimmed in the quarter. The largest:
| Fund | Shares | Value | Change in the quarter |
|---|---|---|---|
| MPM Bioimpact LLC | 4,835,872 | $155.9M | 0 |
| EcoR1 Capital, LLC | 4,824,469 | $155.5M | 0 |
| Blue Owl Capital Holdings LP | 3,070,219 | $99.0M | -91,129 |
| BlackRock, Inc. | 2,278,358 | $73.4M | +166,231 |
| T. Rowe Price Investment Management, Inc. | 2,051,447 | $66.1M | -72,365 |
| Wellington Management Group LLP | 1,966,244 | $63.4M | -350,800 |
| RTW Investments, LP | 1,592,043 | $51.3M | 0 |
| Ra Capital Management, L.P. | 1,314,405 | $42.4M | -188,679 |
| Jupiter Topco LLC | 1,314,267 | $42.4M | – |
| Baker Bros. Advisors LP | 996,351 | $32.1M | 0 |
Peers
Companies in the same industry.
- Eli Lilly & Co. (LLY): revenue $86.5B, market value $1.33T
- Johnson & Johnson (JNJ): revenue $99.3B, market value $657.6B
- AbbVie Inc. (ABBV): revenue $64.4B, market value $521.0B
- Merck & Co., Inc. (MRK): revenue $66.6B, market value $368.9B
- Novartis AG (NVS): revenue $54.5B, market value $306.8B
- AstraZeneca PLC (AZN): revenue $58.7B, market value $289.5B
- Abbott Laboratories (ABT): revenue $46.6B, market value $183.8B
- Novo Nordisk A/S (NVO): revenue $46.8B, market value $178.6B
- Pfizer Inc. (PFE): revenue $63.7B, market value $173.8B
- Vertex Pharmaceuticals Inc. (VRTX): revenue $12.6B, market value $141.6B